Investigators assessed the independent associations of albuminuria and eGFR with overall and site-specific cancers using data from more than one million patients in the Chronic Kidney Disease ...

Men who improve their adherence to ACS guidelines following diagnosis have a reduction in all-cause and cardiovascular mortality compared to those who maintain a low concordance with guideline ...

Overall, 41.7% of cancer deaths in 2023 were attributed to potentially modifiable risk factors, with behavioral risk factors having the greatest impact.

Patients with 15-day MRD less than 10% blasts fared better than those with 10% or greater, even if they had other high-risk factors.

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

HealthDay News — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations, the addition of niraparib to abiraterone acetate ...

Compared to no legalization, medical marijuana legalization with state-run dispensaries appears to increase the risk of adverse hospital events among cancer patients receiving surgery.

The EXCALIBER-RRMM study evaluated the efficacy and safety of iberdomide, an investigational cereblon E3 ligase modulator, in combination with dexamethasone and daratumumab in adults with RRMM.

Our prediction model provides a useful framework for conveying tailored risk information simply and identifying women who may receive enhanced benefit from specific intervention strategies because ...

HealthDay News — From 2003 to 2017, cancer incidence rates increased for several cancer types, with increases in younger and older adults for many cancers, according to a study published online Oct.

A review of JADER and FAERS databases identified common adverse effects for 3 antibody-drug conjugates with the same type of payload.

Researchers sought to determine whether brexucabtagene autoleucel would improve response rates among patients with relapsed or refractory CLL.